Sanofi: EPS up over 12% in Q3
(CercleFinance.com) - Sanofi reports business EPS of E2.
86 for Q3 2024, up 12.2% as reported and up 17.6% at constant exchange rates (CER), on sales of over E13.4bn, up 12.3% (+15.7% CER).
This performance was underpinned by a favourable sales sequence for influenza vaccines and Beyfortus, 67% growth for our new medicines, and volume-driven growth for Dupixent, management explains.
The transformation of our pipeline continues to progress, with four new approvals and four positive Phase 3 results, including for tolebrutinib in secondarily progressive non-active multiple sclerosis, Sanofi continues.
Sanofi says that on Monday, in conjunction with its announcement on Opella, it raised its outlook for 2024, now expecting EPS growth from TCC activities at least in the low single-digit range, underpinned by the strong performance of the business.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
86 for Q3 2024, up 12.2% as reported and up 17.6% at constant exchange rates (CER), on sales of over E13.4bn, up 12.3% (+15.7% CER).
This performance was underpinned by a favourable sales sequence for influenza vaccines and Beyfortus, 67% growth for our new medicines, and volume-driven growth for Dupixent, management explains.
The transformation of our pipeline continues to progress, with four new approvals and four positive Phase 3 results, including for tolebrutinib in secondarily progressive non-active multiple sclerosis, Sanofi continues.
Sanofi says that on Monday, in conjunction with its announcement on Opella, it raised its outlook for 2024, now expecting EPS growth from TCC activities at least in the low single-digit range, underpinned by the strong performance of the business.
Copyright (c) 2024 CercleFinance.com. All rights reserved.